Market
Main competitor to Novo Nordisk in obesity drug market by end of 2025?
3
Resolution / Starting Odds
Eli Lilly • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Market analysis reports and industry publications
Story
Novo Nordisk's Amycretin Achieves 22% Weight Loss in Early Trial, Shares Jump 11%
Jan 24, 2025, 11:05 AM
Novo Nordisk announced positive results from an early-stage clinical trial of its next-generation experimental obesity drug, amycretin. In the phase 1b/2a trial involving 125 participants with overweight or obesity, those treated with amycretin achieved up to 22% weight loss after 36 weeks. Amycretin is a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous injection. Following the announcement, Novo Nordisk's shares surged by as much as 11%, the most in a month.
View original story
Similar markets
Eli Lilly • 33%
Another competitor • 34%
Novo Nordisk • 33%
Outside top 5 • 25%
Top 3 in the sector • 25%
Top 5 in the sector • 25%
Leader in the sector • 25%
Other • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%
Novo Nordisk • 25%
Pfizer • 25%
Eli Lilly • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Eli Lilly > 60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk • 25%
Viking Therapeutics • 25%
Other • 25%
Eli Lilly • 25%
More than 50% • 25%
40% to 50% • 25%
30% to 40% • 25%
Less than 30% • 25%
Novo Nordisk • 25%
Other • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Heart disease • 25%
Brain disorders • 25%
Kidney disease • 25%
Stroke • 25%